Warner-lambert Company

Pfizer Corporation

Zoetis LLC

Basf Aktiengesellsschaft

Joseph Scott Warmus

Haile Tecle

Stephen Douglas Barrett

Timothy Allan Johnson

Michael David Kaufman

Manjinder Singh Lall

Cathlin Marie Biwersi

Robert L Dow

Matthew Frank Brown

Philip Albert Carpino

John C Hodges

Roger B Ruggeri

Clarke Bentley Taylor

Gary Louis Bolton

David Hepworth

Edmund Lee Ellsworth

Michael William Wilson

Matthew Scott Dowling

Richard John Booth

Daniel Wei-Shung Kung

Matthew Forrest Sammons

Sean Timothy Murphy

Denton Wade Hoyer

Mark W Creswell

Debra Ann Sherry

Edward L Conn

Suvi Orr

Charles Francis Donovan

Yan Zhang

Benjamin N Rocke

Michael Aaron Brodney

Patrick Robert Verhoest

Jingrong Jean Cui

Jotham Wadsworth Coe

Christopher John Helal

Peter Laurence Toogood

Bradley W Caprathe

Travis T Wager

Sacha Ninkovic

Thomas Allen Chappie

Jaclyn Louise Henderson

Michael P Curtis

Chris Limberakis

Bethany Lyn Kormos

Robert Ian Storer

Indrawan James McAlpine

Yuan Zhang

Martin Youngjin Pettersson

Asako Nagata

Antonia Friederike Stepan

Sheryl Jeanne Hays

Karen Jean Coffman

Matthew Richard Reese

Paul Galatsis

Robert V Talanian

Sharanjeet Kaur Bagal

Jinshan Michael Chen

Hamish John Allen

Sarah Elizabeth Skerratt

Michelle Renee Garnsey

Nigel P Walker

Kenneth Dale Brady

Ravi G Kurumbail

Timothy Allen Johnson

Michael Huai Gu Chen

Kiyoyuki Omoto

Luis Angel Martinez-Alsina

Jared Bruce John Milbank

Elizabeth Ann Lunney

John Lodge Gilmore

Samantha Elizabeth Greasley

Cathlin Marie Flamme

Chris Lim-Berakis

Colin Richard Rose

Michael Chen

Cathlin Biwersi

Jared Bruce Milbank

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

2-thiopyrimidinones

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L-L, A, B, R-R, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

Hydroxamic acid derivatives useful as antibacterial agents

The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Tropomyosin-related kinase inhibitors

Described herein are antibacterial compounds of formula I, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.

Tricyclic tetrahydroquinoline antibacterial agents

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II); and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B. L-LA, B, R-Rand m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystalline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids

The present invention relates to N-methyl-substituted benzamidazole derivatives of formula (I): as defined in the specification; pharmaceutical compositions and methods of use thereof.

N-methyl-substituted benzamidazoles

Diarylamines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, Calkoxy, or NROR; X is OR, NRR, or NR; inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.

Substituted diarylamines as MEK inhibitors

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids

Rapid purification by polymer supported quench

Novel polymer-supported quenching reagents of Formula (I): P-L-Q, wherein P is a polymer of low chemical reactivity which is soluble or insoluble; Q is one or more quenching reagents, or an acid or base addition salts thereof, that are capable of selective covalent reaction with unwanted byproducts, or excess reagents; and L is one or more chemically robust linkers that join P and Q; are described, as well as methods for their preparation and methods for their use in the rapid purification of synthetic intermediates and products in organic synthesis, combinatorial chemistry and automated organic synthesis.

The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.

Hydroxamate inhibitors of interleukin-1.beta. converting enzyme

Growing community of inventors

Ann Arbor, MI, United States of America

Joseph Scott Warmus